


Defective CYP17A1 causes AH5



Jassal, B., Nakaki, T.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of <u>Creative Commons Attribution 4.0 International (CC BY 4.0)</u> <u>License</u>. For more information see our <u>license</u>.

This is just an excerpt of a full-length report for this pathway. To access the complete report, please download it at the <u>Reactome Textbook</u>.

11/05/2024

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references


- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics, 18,* 142. 7
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. A
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res, 46*, D649-D655. ↗
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, *14*, e1005968. *オ*

This document contains 1 pathway and 3 reactions (see Table of Contents)

Defective CYP17A1 causes AH5 ↗

Stable identifier: R-HSA-5579028

Diseases: adrenal gland disease



Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Common symptoms include mild hypocortisolism, ambiguous genitalia in genetic males or failure of the ovaries to function at puberty in genetic females, metabolic alkalosis due to hypokalemia and low-renin hypertension. CYP17A1 can have defects in either or both of 17-alpha-hydroxylase and 17,20-lyase activities thus patients can show combined partial 17-alpha-hydroxylase/17,20-lyase deficiency or isolated 17,20-lyase deficiency traits (Yanase et al. 1992, Kater & Biglieri 1994, Fluck & Miller 2006, Miller 2012).

Literature references

Miller, WL. (2012). The syndrome of 17,20 lyase deficiency. J. Clin. Endocrinol. Metab., 97, 59-67. 🛪

- Waterman, MR., Yanase, T., Simpson, ER., Imai, T. (1992). Molecular basis of 17?-hydroxylase/17,20-lyase deficiency . J. Steroid Biochem. Mol. Biol., 43, 973-9. ↗
- Biglieri, EG., Kater, CE. (1994). Disorders of steroid 17 alpha-hydroxylase deficiency. *Endocrinol. Metab. Clin. North* Am., 23, 341-57. ↗
- Miller, WL., Flück, CE. (2006). P450 oxidoreductase deficiency: a new form of congenital adrenal hyperplasia. *Curr. Opin. Pediatr.*, 18, 435-41.
- Waterman, MR., Winter, JS., Kagimoto, M., Kagimoto, K., Simpson, ER. (1988). Structural characterization of normal and mutant human steroid 17 alpha-hydroxylase genes: molecular basis of one example of combined 17 alpha-hydroxylase/17,20 lyase deficiency. *Mol. Endocrinol.*, *2*, 564-70. *¬*

2014-06-06	Authored, Edited	Jassal, B.
2014-11-03	Reviewed	Nakaki, T.

Defective CYP17A1 does not 17-hydroxylate PREG 7


Location: Defective CYP17A1 causes AH5

Stable identifier: R-HSA-5601843

Type: transition

Compartments: endoplasmic reticulum membrane, cytosol

Diseases: adrenal gland disease



Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Mutations causing combined 17-alpha-hydroxylase/17,20-lyase deficiency include S106P, R96W, W17*, R362C, W406R and R96Q (Lin et al. 1991, Laflamme et al. 1996, Suzuki et al. 1998, Martin et al. 2003, Brooke et al. 2006). Mutations causing isolated 17,20-lyase deficiency are R358Q and R347H (Geller et al. 1997, Van den Akker et al. 2002).

Literature references

- Martin, RM., de Oliveira, ML., Costa, EM., Villar, H., Lin, CJ., Longui, CA. et al. (2003). P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J. Clin. Endocrinol. Metab., 88, 5739-46.
- Auchus, RJ., Achermann, JC., Papari-Zareei, M., Gore, ME., Ahmad, T., Taylor, NF. et al. (2006). A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab. , 91, 2428-31. 7
- Miller, WL., Auchus, RJ., Mendonça, BB., Geller, DH. (1997). The genetic and functional basis of isolated 17,20-lyase deficiency. *Nat. Genet.*, 17, 201-5.
- Suzuki, Y., Nagashima, T., Nagashima, K., Nomura, Y., Morikawa, A., Onigata, K. (1998). A new compound heterozygous mutation (W17X, 436 + 5G --> T) in the cytochrome P450c17 gene causes 17 alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab., 83, 199-202. 7
- Leblanc, JF., Mailloux, J., Labrie, F., Simard, J., Faure, N., Laflamme, N. (1996). Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J. Clin. Endocrinol. Metab., 81, 264-8.

2014-06-13	Authored, Edited	Jassal, B.
2014-11-03	Reviewed	Nakaki, T.

Defective CYP17A1 does not 17-hydroxylate P4 7


Location: Defective CYP17A1 causes AH5

Stable identifier: R-HSA-9035954

Type: transition

Compartments: endoplasmic reticulum membrane, cytosol

Diseases: adrenal gland disease



Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Mutations causing combined 17-alpha-hydroxylase/17,20-lyase deficiency include S106P, R96W, W17*, R362C, W406R and R96Q (Lin et al. 1991, Laflamme et al. 1996, Suzuki et al. 1998, Martin et al. 2003, Brooke et al. 2006). Mutations causing isolated 17,20-lyase deficiency are R358Q and R347H (Geller et al. 1997, Van den Akker et al. 2002).

Literature references

- Martin, RM., de Oliveira, ML., Costa, EM., Villar, H., Lin, CJ., Longui, CA. et al. (2003). P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J. Clin. Endocrinol. Metab., 88, 5739-46.
- Auchus, RJ., Achermann, JC., Papari-Zareei, M., Gore, ME., Ahmad, T., Taylor, NF. et al. (2006). A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab. , 91, 2428-31. 7
- Miller, WL., Auchus, RJ., Mendonça, BB., Geller, DH. (1997). The genetic and functional basis of isolated 17,20-lyase deficiency. *Nat. Genet.*, 17, 201-5.
- Suzuki, Y., Nagashima, T., Nagashima, K., Nomura, Y., Morikawa, A., Onigata, K. (1998). A new compound heterozygous mutation (W17X, 436 + 5G --> T) in the cytochrome P450c17 gene causes 17 alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab., 83, 199-202. 7
- Leblanc, JF., Mailloux, J., Labrie, F., Simard, J., Faure, N., Laflamme, N. (1996). Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J. Clin. Endocrinol. Metab., 81, 264-8.

2014-06-13	Authored, Edited	Jassal, B.
2014-11-03	Reviewed	Nakaki, T.

Defective CYP17A1 does not cleave 17aHPROG 7


Location: Defective CYP17A1 causes AH5

Stable identifier: R-HSA-9035956

Type: transition

Compartments: endoplasmic reticulum membrane, cytosol

Diseases: adrenal gland disease



Steroid 17-alpha-hydroxylase/17,20 lyase (CYP17A1) mediates both 17-alpha-hydroxylase and 17,20-lyase activity, allowing the adrenal glands and gonads to synthesise both 17-alpha-hydroxylated glucocorticoids and sex steroids respectively (Kagimoto et al. 1998). Defects in CYP17A1 can cause Adrenal hyperplasia 5 (AH5), a form of congenital adrenal hyperplasia (CAH), a common recessive disease due to defective synthesis of cortisol and sex steroids. Mutations causing combined 17-alpha-hydroxylase/17,20-lyase deficiency include S106P, R96W, W17*, R362C, W406R and R96Q (Lin et al. 1991, Laflamme et al. 1996, Suzuki et al. 1998, Martin et al. 2003, Brooke et al. 2006). Mutations causing isolated 17,20-lyase deficiency are R358Q and R347H (Geller et al. 1997, Van den Akker et al. 2002).

Literature references

- Martin, RM., de Oliveira, ML., Costa, EM., Villar, H., Lin, CJ., Longui, CA. et al. (2003). P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J. Clin. Endocrinol. Metab., 88, 5739-46.
- Auchus, RJ., Achermann, JC., Papari-Zareei, M., Gore, ME., Ahmad, T., Taylor, NF. et al. (2006). A novel point mutation in P450c17 (CYP17) causing combined 17alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab. , 91, 2428-31. 7
- Miller, WL., Auchus, RJ., Mendonça, BB., Geller, DH. (1997). The genetic and functional basis of isolated 17,20-lyase deficiency. *Nat. Genet.*, 17, 201-5.
- Suzuki, Y., Nagashima, T., Nagashima, K., Nomura, Y., Morikawa, A., Onigata, K. (1998). A new compound heterozygous mutation (W17X, 436 + 5G --> T) in the cytochrome P450c17 gene causes 17 alpha-hydroxylase/17,20-lyase deficiency. J. Clin. Endocrinol. Metab., 83, 199-202. 7
- Leblanc, JF., Mailloux, J., Labrie, F., Simard, J., Faure, N., Laflamme, N. (1996). Mutation R96W in cytochrome P450c17 gene causes combined 17 alpha-hydroxylase/17-20-lyase deficiency in two French Canadian patients. J. Clin. Endocrinol. Metab., 81, 264-8.

2014-06-13	Authored, Edited	Jassal, B.
2014-11-03	Reviewed	Nakaki, T.

Table of Contents

Introduction	1
Tefective CYP17A1 causes AH5	2
⊣ Defective CYP17A1 does not 17-hydroxylate PREG	4
⊣ Defective CYP17A1 does not 17-hydroxylate P4	6
⊣ Defective CYP17A1 does not cleave 17aHPROG	8
Table of Contents	10